CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 37 enrolled
Drug / intervention
Therapeutic plasma exchangedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01210716
NCT01210716Phase 3Completed
CompareCT.gov

Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device

Fenwal, Inc.·interventional·Posted Sep 28, 2010·Updated Sep 23, 2013

In Brief

A Phase 3 clinical trial evaluating Therapeutic plasma exchange for Autoimmune Diseases and 3 related conditions. Completed, enrolled 37 participants across 4 sites.

Detailed Summary

This study will evaluate the use of the AMICUS device in patients where Therapeutic Plasma Exchange (TPE) is prescribed by their physicians.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutoimmune Diseases, Renal Disorders, Hematologic Disorders, Oncologic Disorders
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 28, 2010
Enrollment StartSep 1, 2010
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.8 years ago

Interventions

Therapeutic plasma exchangedevice

Patients are randomized to either Therapeutic plasma exchange procedures on AMICUS or Spectra first. The second procedure (based on time interval determined by physician) will be completed on the other instrument.